Home Market Jubilant Life Sciences Ltd.

Jubilant Life Sciences Ltd. Stock Info: As on 2018-02-22 15:49:12

Nse

991.80

3.85(0.39%)
Change%
52 Week Range
600.00
25.00
1,039.00
8.00
Open988.00
Day's Range790.36 - 1,185.54
Value Traded (in ₹ Cr.) 92.62

Bse

988.70

1.75(0.18%)
Change %
52 Week Range
600.00
25.00
1,039.00
8.00
Open975.00
Day's Range789.56 - 1,184.34
Value Traded (in ₹ Cr.) 14.89

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 6,970,380.00 4.38%
IndianPromoters 79,080,676.00 49.65%
Mutual Funds/UTI 8,399,997.00 5.27%
FII 32,251,263.00 20.25%
Employee 0.00 0.00%
Public 19,714,662.00 12.38%
Government 0.00 0.00%
Others 8,494,523.00 5.33%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 2.50
Basic EPS (Rs.) 4.96
Cash EPS 10.42
BVPerShare Excl 124.45
Operating Revenue 166.74
PBDITPerShare 25.27
Dividend 3.00
NPPerShare 4.96
Current Ratio 0.89
Quick Ratio 0.49
PriceToBV 3.35
Earnings 0.01
PBDIT Margin 15.15
PBT Margin 3.44
NP Margin 2.97
Return On Assets 1.75
Retention Ratios 39.56
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,717.91
Total Expenses 2,604.57
EBITDA 402.63
PBT 91.41
PAT 79.07
Net Income 79.07
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,289.82
Total Expenses 1,152.62
EBITDA 93.58
PBT 30.19
PAT 20.76
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 15.93
Net worth 1,982.50
Investments 1,706.83
Total Liability 4,503.45
Total debt 1,556.53
Net block 1,446.95
Total Assets 4,503.45
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 15.93
Net worth 1,982.50
Investments 1,706.83
Total Liability 4,503.45
Total debt 1,556.53
Net block 1,446.95
Total Assets 4,503.45
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

607 607.7 -0.12
603.6668.8

Abbott India Ltd.

5754.4 5640.3 2.02
5470.056125

Ajanta Pharma Ltd.

1350.3 1356.45 -0.45
1311.31427.85

Albert David Ltd.

365.2 368.6 -0.92
360.25404.9

Alembic Ltd.

60.8 60.8 0
60.364.4

Alembic Pharmaceuticals Ltd.

563.7 560.85 0.51
546.8589.4

Alkem Laboratories Ltd.

2174.8 2152.95 1.01
2115.12185
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

48.75 49.5 -1.52
4954.6

Aarti Drugs Ltd.

604 607.05 -0.5
605680

Aayush Food & Herbs Ltd.

63.75 63.45 0.47
59.173.4

Abbott India Ltd.

5675 5637.6 0.66
55005950

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 140.37
Cash from investing activities 521.70
Cash from financing activities -760.51
Net change in cash -98.44

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Motilal Oswal MOSt Focused Multicap 35 Fund 4.23%
Canara Robeco Emerging Equities 2.08%
Motilal Oswal MOSt Focused Dynamic Equity Fund 3.47%
Motilal Oswal Most Focused Long Term Fund 5.14%
DSP BlackRock Opportunities Fund 0.85%
Canara Robeco Equity Tax Saver 1.84%

Tata Comm partners Chunghwa telecom to provide IoT experience

Tata Communications, a leading digital infrastructure provider has said that it is joining forces with Chunghwa Telecom, Taiwan’s largest mobile network operator, to bring global connectivity to consumer electronics and industrial Internet of Things (IoT) devices. Tata Communications MOVE - IoT Connect™ allows IoT devices to be deployed quickly both locally and internationally by leveraging Tata Communications’ ecosystem of mobile network operators worldwide. As part of this ecosystem, Chunghwa Telecom will be able to tap into additional revenues by connecting IoT devices through Tata Communications MOVE™. The Taiwanese electronics industry output is expected to be worth USDD 228 billion (NT$6.65 trillion) in 2018, and the wearables market grew at double digits in both volume and value terms in 2017. Chunghwa Telecom looks to capitalise on this growth through the existing IoT roaming services it provides, and by offering its device manufacturer and enterprise customers’ IoT services instant global reach through Tata Communications MOVE - IoT Connect™. Meanwhile, shares of the company were trading at Rs 629 apiece, up 0.58 per cent from the previous close at 10:09 hours on BSE.

22-02-2018 10:01

Godrej Properties adds new residential project in Gurgaon

Godrej Properties Ltd. (GPL), one of India’s leading real estate developers has said that it has expanded its residential portfolio in NCR, with an addition of a new residential project in Gurgaon. This project will offer approximately 70,500 square meters (approximately 7.5 lakh sq. ft.) of saleable area and will be developed as a modern group housing development. This project is situated in an established location within Gurgaon City and has excellent connectivity to the various key micro-markets in Gurgaon. This is GPL’s twelfth project within the National Capital Region (NCR). Within five years of entering the NCR market, Godrej Properties has established itself as one of the market leaders in NCR and hopes to further build on this position. Meanwhile, shares of the company were trading at Rs 773 apiece, up 0.13 per cent from the previous close at 09:27 hours on BSE.

22-02-2018 09:20

Glenmark Pharma enters into agreement with Sam Chun Dang

Glenmark Pharmaceuticals, a global pharmaceutical company has said that it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Ltd. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America. It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the U.S. brand sales for the six products was approximately $1.7 billion for calendar year 2017. Meanwhile, shares of the company were trading at Rs 524 apiece, down 0.13 per cent from the previous close at 09:27 hours on BSE.

22-02-2018 09:19

Allahabad Bank has Rs 517-cr exposure to Rotomac

State-owned Allahabad Bank today said it has an exposure of Rs 516.79 crore to crisis-hit Rotomac group and the lender has made required provisioning for the same as per RBI norms, reported PTI. Responding to a clarification sought by exchanges on news article Rotomac owner flees India after taking Rs 800 crore loans', the Allahabad Bank said the group is having an exposure from our bank since 2006. There is an outstanding of Rs 43.09 crore to Rotomac Exim Pvt Ltd as a sole banker, Rs 314.56 crore to Rotomac Global as multiple banking lending and Rs 159.14 crore to Rotomac Exports as a consortium arrangement with Bank of India as a lead banker. These three loans amount to Rs 516.79 crore. The aforesaid accounts of Rotomac group classified as non-performing assets as per IRAC norms of RBI and the required provision has been made, it said in a regulatory filing. The bank said the accounts of Rotomac Global and Rotomac Exports have been filed in National Company Law Tribunal (NCLT) and was admitted on September 20, 2017. The recovery process under SARFAESI is in process by the bank for the third Rotomac group company, namely, Rotomac Exim Pvt Ltd, it said. A number of banks have made announcements to the stock exchanges clarifying on the news since their names have appeared in the news item earlier this week. Bank of Baroda has an exposure to the tune of 456.60 crore to Rotomac group companies that it declared as bad loans in October 2015 and has already started recovery process by registering the case under Corporate Insolvency Resolution Process at NCLT. Besides, Bank of India, Union Bank of India and Indian Overseas Bank also have their respective exposures to the Rotomac group and they have resorted to the available mechanisms to recover their dues. After the enactment of Insolvency and Bankruptcy Code in 2016, the banks have started going to corporate insolvency resolution process to recover their dues from borrowers. Complaints have already being lodged with the CBI, ED and Directorate of Revenue Intelligence against the Rotomac group. After the CBI and ED, the Income Tax Department has stepped up action against Kanpur-based Rotomac group and its promoter, attaching 11 bank accounts in connection with an alleged tax evasion probe against them.. The accounts of the group in various bank branches in Uttar Pradesh have already been attached by the agencies.

22-02-2018 00:50

Kothari Indl. posts Q3 net loss of Rs 0.78 cr

The company reported standalone net loss during the quarter stood at Rs 0.78 crore as compared to net loss of Rs 0.27 crore in the previous year quarter. Net revenue of the company declined substantially by 29.70 per cent at Rs 7.55 crore in October-December quarter of this fiscal as against Rs 10.74 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 23.56 per cent to Rs 7.98 crore from Rs 10.44 crore in year ago period. Other Income grew by 47.83 per cent at Rs 0.68 crore versus (Dec'16 Rs 0.46 crore). Operating Profit slipped by 243.33 per cent to Rs -0.43 crore as against Rs 0.30 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 302.87 per cent in December quarter.

21-02-2018 17:05

Jubilant Pharma gets USFDA nod for Symmetrel's generic version

Drug firm Jubilant Life Sciences today said its subsidiary has received final approval from the US health regulator for Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug. The approved drug, generic version of Symmetrel of Endo, is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. It is also indicated in the treatment of Parkinsonismand drug-induced extrapyramidal reactions.Jubilant Pharma Ltd, a material wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, has received abbreviated new drug application (ANDA) final approval for Amantadine Hydrochloride tablets, 100 mg, Jubilant Life Sciences said in a BSE filing. This is the ninth approval received by the company from the USFDA during the current financial year.As on December 31, 2017, Jubilant Life Sciences had 86 ANDAs for oral solids filed in the US, of which 56 have been approved and 12 injectable filings, of which 10 had been approved, the filing added.

09-Feb-2018 12:40 PM

Jubilant Life Scienc - Announcement under Regulation 30 (LODR)-Updates

Dear Sirs,

We enclose a communication pertaining to USFDA approval.

This is for your information and records.

09-Feb-2018 11:55 AM

Jubilant Life Scienc - Updates

Jubilant Life Sciences Limited has informed the Exchange regarding ''Dear Sirs,We enclose a communication pertaining to USFDA approval.This is for your information and records.''.

09-Feb-2018 11:54 AM

Jubilant Life Scienc - News Clarification

The Exchange had sought clarification from the Company with respect to news item captioned SEBI Fines Jubliant Life, Senior Officials. The response from the Company is enclosed.

01-Feb-2018 06:35 PM

Jubilant Life Scienc - Updates

Dear Sirs,

We have noted from the SEBI website that by Adjudication Order dated January 31, 2018, a penalty of Rs. 10 Lac has been imposed on each of Jubilant Life Sciences Limited, Jubilant Stock Holding Private Limited, Mr. Shyam Sunder Bhartia and Mr. Hari Shanker Bhartia.

We have not yet received the order and we will evaluate the option of filing an appeal against the said order once we have had the opportunity to review it.

01-Feb-2018 06:34 PM

Jubilant Life Scienc - Announcement under Regulation 30 (LODR)-Updates

Dear Sirs,

We enclose a communication pertaining to USFDA approval.

This is for your information and records.

09-Feb-2018 11:55 AM

Jubilant Life Scienc - Updates

Dear Sirs,

We have noted from the SEBI website that by Adjudication Order dated January 31, 2018, a penalty of Rs. 10 Lac has been imposed on each of Jubilant Life Sciences Limited, Jubilant Stock Holding Private Limited, Mr. Shyam Sunder Bhartia and Mr. Hari Shanker Bhartia.

We have not yet received the order and we will evaluate the option of filing an appeal against the said order once we have had the opportunity to review it.

01-Feb-2018 06:34 PM

Jubilant Life Scienc - Clarification sought from Jubilant Life Sciences Ltd

The Exchange has sought clarification from Jubilant Life Sciences Ltd with respect to news article appearing on The Economic Times - February 1, 2018 titled SEBI Fines Jubliant Life, Senior Officials.

The reply is awaited.

01-Feb-2018 02:30 PM

Corporate Details

About Management

YEAR EVENTS 1978 - The Company was incorporated on 21st June, in Uttar Pradesh. The Company manufacture Vinyl Acetate Monomer (VAM). The Company was promoted by A.B. Bofors (Swedish Multinational), Hindustan Wires Ltd., and Mr. M.L. Bhartia. - The Company entered into a technical collaboration agreement with Noble Chematur Division of A.B. Bofors, Sweden for the supply of know-how and basic engineering for the manufacture of vinyl acetate monomer. 1981 - 1,200 No. of equity shares subscribed for by the signatories to the Memorandum of Association. 34,63,800 No. of equity and 38,500 Pref. shares issued through a prospectus during Mar./Apr. 1982, 19,250 Pref. shares each reserved and allotted to UPSIDC and PICUP. 6,08,370 No. of equity shares reserved and allotted to Indian private promoters and their associates, 6,55,430 No. of equity shares reserved and allotted to AB Brothers of Sweden and 22,00,000 No. of equity shares offered at par for public subscription. Pref. shares redeemable during 28.5.1993/96. 1982 - 6,93,000 Rights Equity shares issued at par in prop. 1:5 (only 5,52,043 shares taken up). The remaining 1,40,357 shares allotted on private placement basis (including 96,800 shares to non-residents). 1983 - Another technical collaboration agreement was signed with Crown Decorative Products Ltd., U.K., and Reed International Company for the manufacture of high pressure emulsions i.e., Polyvinyl Acetate Emulsions. This project was commissioned in 1985-86. - During November, the Company promoted `India Glycols Ltd.' to take up the implementation of a project to manufacture Mono Ethylene Glyco (MEG) at Kashipur, U.P., in technical collaboration with Scientific Design Co. Int., U.S.A. Commercial production commenced on 1st January, 1990. 1984 - A technical collaboration agreement was signed with Technimont Spa of Italy for the manufacture of polyvinyl alcohol with an installed capacity of 2,000 tonnes per annum. The unit was commissioned in July 1991, with an installed capacity of 650 MT per annum. During 1991, the capacity was doubled to 1,400 tonnes per annum. The Company proposed to enhance the capacity of 2,000 MT per annum by installing additional equipment. 1985 - Vam Leasing Ltd., and Vam Investments Ltd., were incorporated as wholly owned subsidiaries of the Company. 1986 - 10,06,180 No. of equity shares issued at par to financial institutions on conversion of loans. 1987 - The Company decided to set up a plant to recover carbon dioxide in collaboration with Hydrogas Denmart a.s. of Denmark and manufacture to dry ice. The plant was commissioned in 1989. A biogas plant was also set up in collaboration with Biotim N.V. of Belgium as a part of energy conservation programme. - The Company also promoted `Insilco Ltd.' jointly with Degussa AG of West Germany for the manufacture of spray dried silica. The project was expected to go on stream by the middle of 1991. - Applications were also submitted to Government for increasing the production capacity of vinyl acetate monomer from 10,000 tonnes to 20,000 tonnes per annum. - In order to part finance the vinyl acetate monomer project, during January, the company privately placed with financial institutions, 15% non-convertible debentures worth Rs 1.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 27th April, 1993. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 1.50 crores. These debentures are redeemable in full at a premium of 5% on 29th December, 1994. 1989 - A synthetic wood adhesive "Vamicol" was launched in January and liquid and dry carbon-di-oxide (dryice) were launched in March. The company installed another new boiler of capacity 25 tonnes steam/hour based on the fluidised bed technology to eliminate air pollution. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 10 crores. These debentures are redeemable in full at a premium of 5% on 25th June, 1996. 1990 - The Company commissioned a plant with an installed capacity of 500 tonnes per annum for the manufacture of pyridine and picoline. - The Company undertook to expand the production capacities of vinyl acetate monomer and its intermediaries i.e., acetic anhydride and acetic acid. The expanded capacities were commissioned in October 1990. - The Company privately placed 14% redeemable non-convertible debentures of Rs 100 each aggregating Rs 5.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 11th September, 1996. - During the year, another 5,00,000-14% redeemable non-convertible debentures of Rs 100 each were privately placed with a provision to redeem at a premium of 5% in three equal instalments commencing on 29th March, 1997. 1992 - Ramganga Fertilizers Ltd. (RFL) was amalgamated with the company effective 1st April, as per BIFR Scheme. As per the scheme of amalgamation 2,56,522 No. of equity shares of Rs 10 each were issued at par to the shareholders of erstwhile RFL in the ratio of one equity share of the company for every 10.35 No. of equity share of Rs 10 each fully paid-up of the erstwhile RFL. 1995 - A technical collaboration agreement was signed with Kemira Coatings Ltd., U.K., to manufacture wood finishes a polymer based product. Another agreement was also signed with M/s. Teutoburg, Germany to manufacture construction chemicals in its plant at Gajraula. - The company proposed to install an additional turbine generator with a capacity of 5.5 MW in view of high and frequently incidence of power failure and fluctuation. The company also proposed to increase the installed capacity of Pyridine & Picolines by 4,000 tonnes per annum to meet the increasing demand for the products. - 2,56,522 No. of equity shares issued to the shareholders of erstwhile RFL on merger of the said company with company. 1996 - The Company proposed to open offices in Singapore to cater to the need of S.E. Asia & China & European markets. With a view to tackling the power failure and fluctuations, the company proposed to instal a turbine generator with a capacity of 5.5 MW. - The company made a capital expenditure of Rs 26.40 crores for taking up projects such as Pyridene & Picolines, wood furnisher, construction chemicals with the intention of saving valuable foreign Exchange. It was also proposed to modernise its sulphuric acid plant. With a view to saving energy the company proposed to instal biogas fired boiler. 1997 - The Company faced a sharp decline in sales realisation of Acetic Acid and VAM, due to a combination of the South East Asian financial debacle and the large capacity build up of Acetic Acid and VAM in South Korean and Singapore. - The company has embarked on a substantial capital expenditure programme to enhance capacities of existing products and also manufacture new products. - Vam Organic Chemicals Ltd has registered a 8.97 per cent increase in net profit for the year ended March 31, 1997 at Rs.23.07 crores as compared to Rs.21.17 crores in the previous year. 1998 - Vam Organics Chemicals has introduced a specialist adhesive Vam Bond 2001. - The dry silica venture, jointly promoted by Vam Organics and Degussa AG of Germany with a 34 per cent stake each has not been doing too well. - The company's performance has been affected due to low international prices, steady increase in prices of major raw materials and sluggish growth in the overall market. - VAM Organic Chemicals Ltd (VOCL) proposes to merge group companies Anichem India Ltd (AIL) and Enpro Speciality Chemicals Ltd (ESCL) with itself. - A planned shut-down of the fertiliser plant was undertaken for 72 days in the quarter for revamping. It also increased its installed capacity from 125 tonnes per day to 175 tonnes per day for sulphuric acid. A captive power plant of 12.45 MW was commissioned in July this year. - VAM Organic Chemicals Ltd is exploring the possibility of entering into areas such as sugar, speciality chemicals and bulk drugs. - The non-convertible debenture programme of Vam Organic Chemicals Ltd has been downgraded by ICRA to LA- LAA-. Vam was the largest player in the alcohol-based organic chemical industry with the largest capacities in the country for most of its products including acetic acid, acetic anhydride, etc. 1999 - VAM Organic Chemicals Ltd (VOCL) has proposed to consolidate and improve its existing position in the chemical industry in the current fiscal. - VOCL has also commissioned the units of Polychem Ltd, manufacturing alcohol-based chemicals in May. - The Company's 22,500 tonnes per annum formaldehyde plant has been commissioned, permitting it to export greater quantities of picolines and pyridines. It has also installed new boilers and increased the capacities of existing plants. 2000 -Enters the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd. 2001 -New corporate identity: Jubilant Organosys Ltd. reflecting changed corporate and business profile 2002 -Acquires the Active Pharmaceutical Ingredients business 2003 -Trading symbol of Jubilant Organosys Limited is changed from 'VAMORGANIC ' to 'JUBILANT' -Jubliant Securites Pvt. Ltd. & Jubliant Capital Pvt. Ltd has acquired 4,38,068 (2.99% of total paid up capital) equity shares. -Mr. H K Khan (Retd. IAS) has been appointed as additional director with effect from November 05, 2003 on the Board. 2004 -Jubilant Organosys Limited has informed that the Board of Directors at their meeting held on January 9, 2004 have approved for voluntary delisting of equity shares of the Company from The Delhi Stock Exchange Association Limited, The Calcutta Stock Exchange Association Limited, Kolkata and the Uttar Pradesh Stock Exchange Association Limited subject to the approval of shareholders by special resolution. -Jubilant Organosys acquires generic pharma Companies in Europe -Jubilant Organosys signs international contracts worth US$ 60 million in CRAMS for the year 2007 2005 -Acquired pharmaceutical company in USA involved in off patent drug development and supply, and owns US FDA approved manufacturing facility for solid dosage forms. -Acquires full service Clinical Research Organization in USA involved in providing clinical research services, data management, biostatistics and contract staffing. -Acquires Target Research Associates, Inc., renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO) -Acquires Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility -Enters Clinsys Clinical Research Ltd. business by setting up wholly owned subsidiary Jubilant Clinsys Ltd. 2006 -Selected as one of the top 25 companies for Institute of Company Secretaries of India National Award for Excellence in Corporate Governance -Finalist in Golden Peacock Award for Excellence in Corporate Governance -Company has splits its Face value of Shares from Rs 5 to Re 1 2007 -Jubilant Organosys Ltd has acquired 100% equity stake in Hollister-Stier Laboratories LLC, USA, engaged in high growth Injectable contract manufacturing and well established and stable Allergy Immunotherapy businesses. -Acquires Hollister Stier Laboratories in USA, a contract manufacturer of Sterile injectable vials and allergenic extracts. 2008 -Acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract manufacturer of sterile & non-sterile products and radiopharmaceuticals -Acquires Speciality Molecules Pvt. Ltd. Engaged in the manufacturing of Fine Chemicals used by Life Science Industry including pharma, agro & cosmetic industry. -Jubilant Organosys and Lilly form Drug development joint venture - Uttar Pradesh-based pharma major Jubilant Organosys Ltd (JOL) has secured new contracts worth $92 million (Rs.3.7 billion). The contracts have been signed under Customs Research and Manufacturing Services (CRAMS). Besides marketing its products in the regulated markets of the US, Europe and Japan, the company has managed to make forays into China, said a statement of JOL. 2009 -Jubilant enters into multiple Drug discovery partnerships with leading pharma and biotech -companies such as AstraZeneca, Orion, Endo pharmaceuticals & BioLeap and also extends its collaboration with Lilly for five years. -Jubilant enters into drug development collaborations with academia, University of Alabama at Birmingham and Southern Research Institute (USA) and Duke University (Singapore). -Jubilant Kalpataru - 120 bed super specialty hospital at Barasat, Kolkata, India inaugurated by Hon'ble Minister of Finance Shri Pranab Mukherjee 2010 -ET - IMEA 2009 Platinum Award by Frost & Sullivan, in the Pharmaceutical category for the API facility at Nanjangud -Best CFO (FMCG, Health and Retail Sector) to Mr. R. Sankaraiah by Institute of Chartered Accountants of India in January, 2010 - Jubilant Organosys Ltd has appointed Mr. Shardul S. Shroff as Additional Director of the Company with effect from March 15, 2010. - Jubilant Organosys Ltd has signed a USD 51 million CRAMS contract with a leading Life Sciences Company 2010 -The Company has changed from "Jubilant Organosys Ltd" to "JUBILANT LIFE SCIENCES LTD" -Mr. Shardul S. Shroff has been appointed as Additional Director of the Company. 2011 -Jubilant Life Sciences Ltd has announced another successful delivery of an early stage milestone in the Pain therapeutic area. -Jubilant Org - Jubilant sets up global scale capacities for Symtet - developed through 2012 -JubilantLife - announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford. -"Jubilant HollisterStier Announces Multi-Million Dollar Award for the manufacture of Sterile Parenteral Products". -"Jubilant SEZ at Bharuch, inaugurated by Shri Narendra Modi, Hon'ble Chief Minister of Gujarat". 2013 - "Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility." - Jubilant Life Sciences receives ANDA approval for Quetiapine Fumarate Tablet -Jubilant Life Sciences declared winner of Supply Chain Excellence Awards' at 7th Express, Logistics & Supply Chain Leadership Awards 2013 2014 - Jubilant Life Scienc - Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc. - Board recommended a Dividend of Rs.3 per equity shares of Rs.1 -Jubilant Life Sciences wins Excellence Awards at `India Pharma Awards' 2014 -Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014 2015 -Gold Award in Ankleshwar Chapter Convention on Quality Concepts 2015 (ACCQC) -Two Honors at the 10th Annual CIO100 Awards by CIO Magazine - CIO100 Innovation Architect Special Awards 2015 and Versatile 100honorees -Golden Peacock National Quality Award for Quality -Dataquest Business Technology Awards for Best IT Implementation in Analytics, Mobility, Cloud, ERP/CSM/CRM -ASSOCHAM's `Responsible Organization Excellence' Award 2014-15 -50 Most Talented Sustainability Leaders Award -15th Annual Greentech Environment Award 2014 - Gold Category winner under Chemicals and Pharmaceutical sector" - Gajraula plant, India -I.C.O.N.I.C IDC Insights Award, under `Health and Life Sciences vertical 2016 - Jubilant Life Sciences Limited won the Sustainability Award for Best Green Process in Chemical sector of FICCI Chemicals & Petrochemicals Awards, 2016.

Registered Office

Bhartiagram, Gajraula

5924-252351,252356,252358,      5924-252352,

investors@jubl.com

http://www.jubl.com

Registrar Details

Alankit Assignment Ltd.